pancreatic adenocarcinoma (Cancer)
Information
- Disease name
- pancreatic adenocarcinoma
- Disease ID
- DOID:4074
- Description
- "A pancreatic carcinoma that derives_from epithelial cells of glandular origin." [url:http\://en.wikipedia.org/wiki/Adenocarcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
| NCT04837118 | Active, not recruiting | N/A | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study | February 15, 2021 | December 31, 2026 |
| NCT01013649 | Active, not recruiting | Phase 3 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | April 5, 2010 | February 13, 2025 |
| NCT05973331 | Active, not recruiting | Prospective Validation of an EHR-based Pancreatic Cancer Risk Model | July 17, 2023 | September 2026 | |
| NCT05451849 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | June 21, 2022 | October 30, 2028 |
| NCT03033927 | Active, not recruiting | Predicting Effective Therapy in Pancreatic Cancer | January 24, 2017 | January 24, 2025 | |
| NCT03816358 | Active, not recruiting | Phase 1 | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | December 9, 2019 | January 31, 2025 |
| NCT02879318 | Active, not recruiting | Phase 2 | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma | November 7, 2016 | December 31, 2024 |
| NCT03193190 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | July 5, 2017 | October 31, 2026 |
| NCT03138720 | Active, not recruiting | Phase 2 | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer | May 23, 2017 | December 1, 2024 |
| NCT04137536 | Active, not recruiting | Phase 1 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | October 17, 2019 | April 2025 |
| NCT02206360 | Active, not recruiting | Pancreatic Cancer Early Detection Program | April 2014 | June 2024 | |
| NCT05239182 | Active, not recruiting | Phase 2 | 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma | January 26, 2022 | June 30, 2025 |
| NCT03404960 | Active, not recruiting | Phase 1/Phase 2 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | January 31, 2018 | June 2026 |
| NCT02723331 | Active, not recruiting | Phase 2 | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | December 30, 2016 | May 2024 |
| NCT02336087 | Active, not recruiting | Phase 1 | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery | January 14, 2016 | December 31, 2024 |
| NCT03483038 | Active, not recruiting | Phase 2 | A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | December 13, 2018 | December 2024 |
| NCT03851614 | Active, not recruiting | Phase 2 | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | April 8, 2019 | January 1, 2025 |
| NCT03225989 | Active, not recruiting | Phase 1/Phase 2 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | March 1, 2018 | August 22, 2024 |
| NCT02775786 | Active, not recruiting | N/A | Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma | November 2013 | December 2025 |
| NCT04257448 | Active, not recruiting | Phase 1/Phase 2 | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | May 25, 2020 | March 2024 |
| NCT03245541 | Active, not recruiting | Phase 1/Phase 2 | Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer | August 14, 2020 | September 2024 |
| NCT03678883 | Active, not recruiting | Phase 2 | 9-ING-41 in Patients With Advanced Cancers | January 4, 2019 | November 2025 |
| NCT04143152 | Active, not recruiting | Pancreatic Cancer Biomarker Study | January 1, 2021 | October 31, 2024 | |
| NCT01753479 | Completed | N/A | Spectroscopy From Duodenum | January 2013 | June 30, 2016 |
| NCT01764477 | Completed | Phase 1 | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | April 2013 | October 2015 |
| NCT01764659 | Completed | 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation | July 2013 | October 2014 | |
| NCT01765036 | Completed | N/A | Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma | July 2009 | September 2010 |
| NCT01783171 | Completed | Phase 1 | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | January 15, 2013 | July 12, 2016 |
| NCT01825603 | Completed | Phase 1 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | April 9, 2013 | June 1, 2017 |
| NCT01834170 | Completed | Phase 1 | EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer | April 2013 | December 2014 |
| NCT01839799 | Completed | Phase 2 | A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma | April 2013 | July 2017 |
| NCT06055647 | Completed | HER-2 Expression in Pancreatic Duct Adenocarcinoma | January 1, 2017 | December 31, 2020 | |
| NCT01959672 | Completed | Phase 2 | Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | September 6, 2013 | December 1, 2018 |
| NCT01989624 | Completed | PAncreatic Adenocarcinoma in Hospital | October 18, 2013 | December 2020 | |
| NCT02045589 | Completed | Phase 1 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | January 2014 | September 2018 |
| NCT02045602 | Completed | Phase 1 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | January 2014 | January 2020 |
| NCT00288093 | Completed | Phase 1 | 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery | December 20, 2006 | December 28, 2012 |
| NCT05305001 | Completed | Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico | September 9, 2020 | June 30, 2022 | |
| NCT02174887 | Completed | Phase 1 | Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer | September 2014 | October 2016 |
| NCT02333188 | Completed | Phase 1 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | December 2014 | December 2017 |
| NCT05226572 | Completed | Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results | July 1, 2017 | May 23, 2022 | |
| NCT02349867 | Completed | Phase 1 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | January 29, 2015 | May 13, 2022 |
| NCT04992507 | Completed | Phase 2 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | June 2, 2023 | January 26, 2024 |
| NCT02394535 | Completed | Phase 1 | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | November 12, 2015 | August 31, 2022 |
| NCT02427841 | Completed | Phase 2 | Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | January 21, 2016 | December 12, 2022 |
| NCT02514421 | Completed | Phase 1 | Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma | July 2015 | April 18, 2017 |
| NCT02550327 | Completed | Early Phase 1 | Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | January 2016 | June 14, 2021 |
| NCT02562716 | Completed | Phase 2 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | January 6, 2016 | September 26, 2022 |
| NCT02586987 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | December 28, 2015 | September 20, 2019 |
| NCT00327327 | Completed | Phase 1 | Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma | February 2004 | October 2009 |
| NCT02620423 | Completed | Phase 1 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | December 2015 | August 2018 |
| NCT02680990 | Completed | N/A | Resilience and Exercise in Advanced Cancer Treatment | December 2015 | July 2017 |
| NCT04406571 | Completed | Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer | April 1, 2020 | May 31, 2022 | |
| NCT04400383 | Completed | Phase 1 | Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | June 4, 2020 | September 28, 2023 |
| NCT04298242 | Completed | N/A | Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment | November 22, 2020 | June 15, 2021 |
| NCT04289961 | Completed | N/A | PDAC Peripheral and Portal Vein Sampling | June 12, 2019 | April 6, 2023 |
| NCT02749136 | Completed | Phase 2 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | May 2016 | November 2019 |
| NCT00574977 | Completed | Phase 1 | Safety Study of Modified Vaccinia Virus to Cancer | May 2008 | July 2014 |
| NCT02806687 | Completed | Phase 2 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer | January 30, 2017 | June 30, 2022 |
| NCT04236102 | Completed | N/A | KEBI-Cyto Study - Use of the Biocartis Idylla | July 7, 2020 | March 7, 2022 |
| NCT04483349 | Completed | Assessment of What Patients and Healthcare Providers Value | June 11, 2020 | August 11, 2022 | |
| NCT03665441 | Completed | Phase 3 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC | September 15, 2018 | January 18, 2022 |
| NCT03415854 | Completed | Phase 2 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) | January 31, 2018 | December 11, 2023 |
| NCT03578445 | Completed | N/A | Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions | February 1, 2018 | August 31, 2019 |
| NCT03567863 | Completed | N/A | Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles | June 24, 2018 | September 29, 2019 |
| NCT03559348 | Completed | Phase 2 | Locally Advanced or Metastatic Pancreatic Adenocarcinoma | April 3, 2018 | April 20, 2020 |
| NCT00638612 | Completed | Phase 1 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | August 2008 | June 2015 |
| NCT00644254 | Completed | The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma | October 2007 | March 2008 | |
| NCT00769483 | Completed | Phase 1/Phase 2 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | November 13, 2008 | September 1, 2020 |
| NCT00854477 | Completed | Phase 4 | Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma | November 2009 | August 2012 |
| NCT00909103 | Completed | Endoscopic Ultrasound Elastography in Pancreatic Masses | June 2008 | December 2009 | |
| NCT01016483 | Completed | Phase 1/Phase 2 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | November 30, 2009 | April 30, 2015 |
| NCT01144455 | Completed | Phase 2 | Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma | June 2010 | December 2014 |
| NCT01274455 | Completed | Phase 1 | Gene Therapy of Pancreatic Ductal Adenocarcinoma | December 2010 | March 2013 |
| NCT00203892 | Completed | Phase 1/Phase 2 | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma | April 2003 | May 2012 |
| NCT01369420 | Completed | Phase 2 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | May 2011 | September 2012 |
| NCT01389440 | Completed | Phase 2 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | May 2011 | January 22, 2017 |
| NCT01474564 | Completed | Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma | November 2011 | October 2019 | |
| NCT01543412 | Completed | Phase 2 | Second Line Chemotherapy for Advanced Pancreatic Cancer | January 2010 | December 2011 |
| NCT01558869 | Completed | Phase 2 | Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma | April 2012 | December 2016 |
| NCT01660711 | Completed | Phase 2 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | July 2012 | August 22, 2018 |
| NCT01674556 | Completed | Phase 1 | Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer | February 2012 | January 2015 |
| NCT01699698 | Completed | N/A | Pancreatic Juice Diagnosis From Duodenum | October 2012 | |
| NCT01726582 | Completed | Phase 2 | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | November 2011 | April 11, 2022 |
| NCT03105921 | Completed | N/A | Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma | October 24, 2014 | April 1, 2021 |
| NCT03126435 | Completed | Phase 3 | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX | October 16, 2018 | October 8, 2021 |
| NCT03871790 | Completed | Peptide-based Immunization for Colon- and and Pancreas-carcinoma | April 1, 2019 | August 31, 2022 | |
| NCT03147768 | Completed | Phase 1 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study | January 1, 2018 | December 31, 2021 |
| NCT03152487 | Completed | N/A | Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis | April 24, 2017 | August 1, 2018 |
| NCT03745430 | Completed | Phase 1/Phase 2 | RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | January 29, 2019 | April 23, 2023 |
| NCT03266757 | Completed | Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma | February 11, 2016 | February 11, 2018 | |
| NCT03307148 | Completed | Phase 1 | Stromal TARgeting for PAncreatic Cancer (STAR_PAC) | January 15, 2016 | March 19, 2019 |
| NCT03307564 | Completed | N/A | Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer | June 6, 2018 | December 31, 2022 |
| NCT03318497 | Completed | Phase 2 | Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma | December 11, 2017 | June 15, 2021 |
| NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
| NCT03373188 | Completed | Phase 1 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | December 15, 2017 | October 28, 2021 |
| NCT04119362 | Completed | PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer | October 24, 2019 | June 30, 2023 | |
| NCT02896907 | Completed | Early Phase 1 | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | October 18, 2016 | March 2019 |
| NCT02896946 | Completed | N/A | Diffusion MRI for Pancreatic Adenocarcinoma | February 2011 | |
| NCT03054987 | Completed | N/A | Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction | September 2016 | October 2018 |
| NCT00154791 | Completed | Phase 1/Phase 2 | Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma | March 2003 | August 2005 |
| NCT06102889 | Enrolling by invitation | GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES | May 2, 2024 | December 31, 2026 | |
| NCT06157671 | Enrolling by invitation | The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma | January 31, 2024 | June 1, 2030 | |
| NCT04814251 | Not yet recruiting | Portal Vein Thrombosis Associated With Unresectable Pancreatic Cancers : a Prospective Multicentric Cohort Study | March 2021 | December 2024 | |
| NCT06387342 | Not yet recruiting | Phase 2 | Namodenoson Treatment of Advanced Pancreatic Cancer | July 15, 2024 | December 15, 2026 |
| NCT06217666 | Not yet recruiting | Phase 1 | Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) | October 31, 2024 | January 1, 2028 |
| NCT04835064 | Not yet recruiting | Phase 3 | Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. | April 1, 2021 | December 1, 2024 |
| NCT06399757 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | May 2024 | May 2027 |
| NCT04926467 | Not yet recruiting | Phase 2 | Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) | June 2021 | June 2026 |
| NCT06026943 | Not yet recruiting | N/A | Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer | September 2024 | January 2028 |
| NCT06412510 | Not yet recruiting | Phase 1/Phase 2 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | June 1, 2024 | February 10, 2025 |
| NCT06333314 | Not yet recruiting | Phase 2 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | May 2024 | September 2030 |
| NCT05287347 | Not yet recruiting | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | October 2024 | October 31, 2027 | |
| NCT06440005 | Recruiting | Phase 1 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | May 2024 | May 2027 |
| NCT01365169 | Recruiting | N/A | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | May 25, 2011 | June 30, 2027 |
| NCT02070705 | Recruiting | N/A | DCE MRI in Patients With Pancreatic Cancer | January 31, 2014 | December 31, 2024 |
| NCT02611024 | Recruiting | Phase 1/Phase 2 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | May 6, 2016 | March 2026 |
| NCT02757859 | Recruiting | N/A | High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | April 27, 2016 | January 2025 |
| NCT03073785 | Recruiting | Phase 2 | Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | September 16, 2016 | December 2027 |
| NCT03080974 | Recruiting | Phase 2 | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | August 14, 2017 | April 1, 2026 |
| NCT03384238 | Recruiting | Phase 1/Phase 2 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | February 7, 2018 | September 2027 |
| NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
| NCT03740256 | Recruiting | Phase 1 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | December 14, 2020 | December 30, 2038 |
| NCT03856658 | Recruiting | Phase 2 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | February 5, 2019 | April 2026 |
| NCT04002479 | Recruiting | N/A | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer | October 20, 2020 | October 2026 |
| NCT04098237 | Recruiting | Phase 2 | Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency | December 17, 2020 | December 2025 |
| NCT04157127 | Recruiting | Phase 1 | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma | August 3, 2020 | November 2027 |
| NCT04167007 | Recruiting | Phase 3 | FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX | July 20, 2020 | July 2025 |
| NCT04303403 | Recruiting | Phase 1 | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | July 31, 2018 | March 31, 2024 |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT04436679 | Recruiting | INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors | February 2, 2021 | February 2025 | |
| NCT04452461 | Recruiting | Phase 2 | Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery | March 1, 2021 | May 1, 2026 |
| NCT04539808 | Recruiting | Phase 2 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | May 27, 2021 | October 5, 2025 |
| NCT04548752 | Recruiting | Phase 2 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | February 22, 2021 | March 31, 2025 |
| NCT04605913 | Recruiting | Phase 1/Phase 2 | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | April 1, 2022 | March 2026 |
| NCT04627246 | Recruiting | Phase 1 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | September 11, 2020 | September 2028 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT04895709 | Recruiting | Phase 1/Phase 2 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | May 27, 2021 | September 15, 2026 |
| NCT04902352 | Recruiting | N/A | The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer | April 6, 2021 | October 6, 2024 |
| NCT04986930 | Recruiting | Phase 2 | mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma | August 14, 2021 | August 14, 2025 |
| NCT05000294 | Recruiting | Phase 1/Phase 2 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | December 7, 2021 | December 2025 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05077800 | Recruiting | Phase 2 | FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | March 21, 2022 | July 31, 2026 |
| NCT05083247 | Recruiting | Phase 2 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma | March 24, 2023 | December 31, 2030 |
| NCT05181605 | Recruiting | Phase 2/Phase 3 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | April 15, 2022 | December 1, 2024 |
| NCT05245500 | Recruiting | Phase 1/Phase 2 | Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | June 2, 2022 | April 30, 2026 |
| NCT05247164 | Recruiting | N/A | EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients | May 17, 2022 | March 2027 |
| NCT05268692 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | January 1, 2019 | December 31, 2030 |
| NCT05351983 | Recruiting | N/A | Patient-derived Organoids Drug Screen in Pancreatic Cancer | September 22, 2022 | June 2023 |
| NCT05365581 | Recruiting | Phase 1 | A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer | June 7, 2022 | June 30, 2026 |
| NCT05400681 | Recruiting | Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer | August 1, 2020 | December 31, 2024 | |
| NCT05482516 | Recruiting | Phase 3 | Evaluating Novel Therapies in ctDNA Positive GI Cancers | March 29, 2023 | December 2028 |
| NCT05494866 | Recruiting | Phase 1 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | December 7, 2022 | February 28, 2025 |
| NCT05585320 | Recruiting | Phase 1/Phase 2 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | October 31, 2022 | June 2027 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT05624918 | Recruiting | Phase 2 | A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma | June 2024 | August 2028 |
| NCT05657743 | Recruiting | N/A | A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer | August 16, 2023 | November 2025 |
| NCT05673811 | Recruiting | Phase 2 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer | January 10, 2023 | April 28, 2025 |
| NCT05737706 | Recruiting | Phase 1/Phase 2 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | March 20, 2023 | August 30, 2026 |
| NCT05752812 | Recruiting | The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer | March 1, 2023 | November 2026 | |
| NCT05776342 | Recruiting | Prognostic and Predictive Markers of Treatment Response in Patients With PAC. | January 1, 2003 | December 31, 2031 | |
| NCT05795595 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | March 13, 2023 | May 2030 |
| NCT05877599 | Recruiting | Phase 1 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | July 27, 2023 | August 2039 |
| NCT05988918 | Recruiting | Phase 2 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | April 19, 2024 | April 2029 |
| NCT06024824 | Recruiting | Phase 1/Phase 2 | Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) | January 30, 2024 | July 2031 |
| NCT06055010 | Recruiting | Improving Pancreatic Cancer Care by the Use of Computational Science and Technology | January 1, 2014 | December 31, 2029 | |
| NCT06095141 | Recruiting | Phase 2/Phase 3 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency | December 1, 2023 | October 31, 2026 |
| NCT06115499 | Recruiting | Phase 2/Phase 3 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | December 6, 2023 | December 9, 2029 |
| NCT06135649 | Recruiting | Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy | January 2013 | December 2024 | |
| NCT06149689 | Recruiting | Phase 2 | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer | January 10, 2024 | October 31, 2026 |
| NCT06199895 | Recruiting | Phase 2 | Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer | November 28, 2023 | November 2025 |
| NCT06219941 | Recruiting | Phase 2 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | December 13, 2023 | January 19, 2027 |
| NCT06250972 | Recruiting | Phase 3 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer | May 15, 2024 | May 1, 2028 |
| NCT06349044 | Recruiting | N/A | A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. | March 20, 2024 | December 31, 2025 |
| NCT06388967 | Recruiting | Pancreatic Cancer Detection Consortium | March 15, 2023 | November 21, 2025 | |
| NCT06405490 | Recruiting | Phase 2 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | April 17, 2024 | December 30, 2026 |
| NCT00637364 | Suspended | Phase 1/Phase 2 | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain | March 2008 | |
| NCT03784417 | Terminated | N/A | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma | October 15, 2019 | December 15, 2021 |
| NCT02124369 | Terminated | Phase 2 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) | July 2014 | December 2017 |
| NCT00593008 | Terminated | Phase 1 | Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer | October 2007 | October 2009 |
| NCT02495896 | Terminated | Phase 1 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | September 3, 2015 | May 29, 2019 |
| NCT02202785 | Terminated | Phase 2 | A Study of MLN0264 in Patients With Pancreatic Cancer | July 2, 2014 | January 15, 2016 |
| NCT03451773 | Terminated | Phase 1/Phase 2 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | May 17, 2018 | May 5, 2020 |
| NCT04983407 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | July 28, 2021 | August 14, 2023 |
| NCT02345460 | Terminated | Phase 2 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | September 2015 | March 2016 |
| NCT04060342 | Terminated | Phase 1 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | August 13, 2019 | April 11, 2022 |
| NCT04077372 | Terminated | N/A | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | September 16, 2019 | October 11, 2020 |
| NCT05546411 | Terminated | Phase 2 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | January 6, 2023 | October 13, 2023 |
| NCT02707328 | Terminated | Phase 1 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | January 2015 | November 10, 2017 |
| NCT05769959 | Terminated | Phase 1/Phase 2 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | June 15, 2023 | March 19, 2024 |
| NCT03592264 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors | June 7, 2018 | March 21, 2024 |
| NCT02838966 | Terminated | N/A | Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation) | August 2014 | November 11, 2019 |
| NCT02207985 | Terminated | Phase 1/Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation in Pancreatic Adenocarcinoma | January 2007 | June 1, 2017 |
| NCT02638909 | Terminated | Phase 2 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | December 2015 | March 29, 2018 |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT01419002 | Terminated | Phase 3 | Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer | October 2011 | October 2014 |
| NCT01206296 | Terminated | Phase 2 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | August 2010 | February 2014 |
| NCT02743975 | Terminated | Phase 1/Phase 2 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma | December 1, 2016 | May 1, 2018 |
| NCT02736578 | Terminated | Phase 2 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | July 2016 | May 22, 2017 |
| NCT03376659 | Terminated | Phase 1/Phase 2 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | August 8, 2018 | August 1, 2023 |
| NCT06341725 | Terminated | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | February 15, 2018 | September 11, 2018 | |
| NCT01897454 | Terminated | Phase 2 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | January 27, 2012 | November 1, 2021 |
| NCT00598091 | Terminated | Phase 1 | A Phase I/Expansion Study of Dasatinib | April 2007 | May 2012 |
| NCT03723915 | Terminated | Phase 2 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | November 14, 2018 | April 24, 2021 |
| NCT05380557 | Terminated | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing | August 23, 2021 | September 6, 2022 | |
| NCT01921751 | Terminated | Phase 2 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | August 2013 | June 2016 |
| NCT04773769 | Unknown status | N/A | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | November 7, 2018 | November 2023 |
| NCT02072616 | Unknown status | Phase 3 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. | September 2014 | September 2021 |
| NCT01971281 | Unknown status | Phase 1/Phase 2 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | November 2013 | December 2017 |
| NCT03507998 | Unknown status | Phase 1 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | June 17, 2017 | April 1, 2021 |
| NCT03517332 | Unknown status | Circulating Tumor DNA Exposure in Peripheral Blood | January 1, 2015 | December 31, 2019 | |
| NCT03528785 | Unknown status | Phase 2 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer | March 2, 2018 | November 1, 2022 |
| NCT03468244 | Unknown status | N/A | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | May 1, 2018 | December 31, 2021 |
| NCT03570502 | Unknown status | Incidence of POPF in the Resection of the Left Pancreas With RFAT | November 2016 | April 2021 | |
| NCT03435770 | Unknown status | N/A | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | March 1, 2018 | September 1, 2019 |
| NCT03401827 | Unknown status | Phase 4 | The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer | March 1, 2018 | January 1, 2019 |
| NCT03673423 | Unknown status | Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer | September 5, 2018 | May 5, 2019 | |
| NCT03703063 | Unknown status | Phase 1 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | September 17, 2018 | September 17, 2022 |
| NCT03703089 | Unknown status | Phase 1 | Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology | May 1, 2018 | May 1, 2023 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT03202199 | Unknown status | N/A | Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma. | June 19, 2017 | July 1, 2021 |
| NCT03840460 | Unknown status | A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers | January 10, 2019 | January 10, 2023 | |
| NCT03159819 | Unknown status | N/A | Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma | April 1, 2017 | December 31, 2021 |
| NCT03140592 | Unknown status | Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue | January 14, 2015 | January 2023 | |
| NCT03063554 | Unknown status | N/A | EUS BD vs ERCP TP for Pancreatic Cancer | October 18, 2016 | October 1, 2018 |
| NCT05228808 | Unknown status | Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma | February 1, 2022 | December 1, 2022 | |
| NCT02839343 | Unknown status | Phase 2 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | December 2016 | |
| NCT01919151 | Unknown status | Micrometastasis in Gastrointestinal Cancer | June 2008 | December 2015 | |
| NCT02818829 | Unknown status | Biological and Clinical Database for Pancreatic Adenocarcinoma | March 2014 | July 2021 | |
| NCT02781012 | Unknown status | Project Survival-Prospective Biomarker Discovery | March 2016 | February 2022 | |
| NCT04400357 | Unknown status | N/A | Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors | June 15, 2020 | November 30, 2022 |
| NCT02707315 | Unknown status | Early Phase 1 | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer | January 2013 | |
| NCT02133079 | Unknown status | Phase 1/Phase 2 | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 | March 2012 | November 2019 |
| NCT04765410 | Unknown status | The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma | March 21, 2019 | June 1, 2021 | |
| NCT02575508 | Withdrawn | Phase 1/Phase 2 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | ||
| NCT03865563 | Withdrawn | Phase 1 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | July 2019 | December 2021 |
| NCT02592395 | Withdrawn | Phase 1 | Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma | October 2015 | October 2017 |
| NCT03649035 | Withdrawn | Phase 3 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | July 12, 2018 | December 31, 2020 |
| NCT05056805 | Withdrawn | N/A | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study | March 4, 2021 | September 8, 2022 |
| NCT00728000 | Withdrawn | Phase 2 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | August 2008 | August 2010 |
| NCT04270929 | Withdrawn | Phase 1 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma | December 23, 2019 | May 4, 2021 |
| NCT04130399 | Withdrawn | Phase 2 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer | July 1, 2019 | January 1, 2023 |
| NCT02496832 | Withdrawn | N/A | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo | November 2014 | November 2014 |
| NCT02850874 | Withdrawn | Phase 2 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | February 2016 | December 2016 |
- Disase is a (Disease Ontology)
- DOID:4905
- Cross Reference ID (Disease Ontology)
- NCI:C8294
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:700423003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0281361
- Exact Synonym (Disease Ontology)
- pancreas adenocarcinoma
- Disase Synonym (Disease Ontology)
- adenocarcinoma of the pancreas
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006725